Adenosine A2b Receptor Agonist for the Treatment of Musculoskeletal Conditions

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the use of adenosine A2B receptor agonists as a novel treatment for diseases of the musculoskeletal system and connective tissue, especially sarcopenia. These agonists, such as BAY 60-6583 and related compounds, work by stimulating the A2B receptor, which has been shown to increase muscle oxygen consumption, glucose uptake, muscle mass, muscle strength, and the regenerative capacity of muscle via satellite cells. This pharmacological approach offers a new potential therapy where few effective drugs currently exist, particularly for age-related muscle loss (sarcopenia).

Use CasesContent extracted from patent full text and abstract with AI.

• Pharmaceutical treatment for age-related sarcopenia to prevent or reverse muscle loss in elderly patients.
• Therapy for muscle wasting diseases or syndromes not limited to old age, such as disease-related or inactivity-induced sarcopenia.
• Supportive treatment to enhance muscle recovery after injury or surgery through improved muscle regeneration.
• Potential intervention for conditions with musculoskeletal weakness, such as osteoporosis, obesity-related muscle degeneration, or diabetes-associated muscle loss.
• Therapeutic agents to aid rehabilitation and maintain mobility in patients at risk of disability and immobility due to muscle degeneration.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a new pharmacological treatment option for sarcopenia where currently few effective drugs are available.
• Demonstrates increased muscle oxygen consumption and glucose uptake, which may enhance muscle function and energy metabolism.
• Improves muscle mass and strength, potentially restoring physical capability in elderly or chronically ill patients.
• Enhances regeneration capacity of skeletal muscle by increasing satellite cell numbers, supporting faster and more effective muscle repair after injury.
• Potentially reduces the risk of comorbidities and adverse outcomes related to sarcopenia such as falls, frailty, hospitalization, and increased healthcare costs.
• May be administered through various routes (oral, transdermal, injectable, etc.), offering flexibility for different patient needs and contexts.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Die vorliegende Erfindung betrifft neue Behandlungsstrategien von Krankheiten des Muskel-Skelett-Systems und des Bindegewebes, insbesondere von Sarkopenie, welche auf der Aktivierung des Adenosin-A2B-Rezeptors basieren.